Levitee Labs acquiring 51% interest in new R&D compounding pharmacy in Calgary, Alberta, Canada New pharmacy to focus on production of intranasal ketamine and sublingual preparations, topical and transdermal formulations, capsules and other Levitee-branded compounds and products Levitee Labs Inc. an integrative wellness company with a diversified portfolio of healthcare and wellness assets, has signed a letter of ...
  • Levitee Labs acquiring 51% interest in new R&D compounding pharmacy in Calgary, Alberta, Canada
  • New pharmacy to focus on production of intranasal ketamine and sublingual preparations, topical and transdermal formulations, capsules and other Levitee-branded compounds and products

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the " Company " or " Levitee "), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, has signed a letter of intent ("LOI") to acquire 51% of the issued and outstanding shares of a new pharmacy with compounding capacities in Alberta (the "Compounding Pharmacy"). The Compounding Pharmacy is led by an expert pharmacy operator with deep experience in the compounding space.

The Compounding Pharmacy is a licensed Level C non-sterile compounding lab adjacent to a separate compounding space and retail pharmacy. The separate compounding space and retail pharmacy was part of an acquisition announced by Levitee Labs on October 12 th , 2021. Through licensed compounding services, a pharmacy creates custom medications from base ingredients for patients, which Levitee Laboratories will use to expand the therapeutic options available to patients and physicians – this will fill gaps in health care for specific needs.

The Company will provide a variety of innovative delivery methods and unique forms of dosage such as intranasal ketamine and sublingual preparations, topical and transdermal formulations, capsules, suppositories, oral liquids and lollipops. The initial focus for formulations is on addiction treatment, mental healthcare, and pain management, with plans to expand the scope of work to other areas.

The acquisition represents the launch of the Company's initiative into production and distribution of pharmaceutical products under the Levitee Labs banner. The Compounding Pharmacy will be used to expand Levitee Labs' operations by introducing a R&D laboratory for the discovery and production of cutting-edge ketamine and psychedelic medicines (when permitted by law) for the safe and effective treatment of addiction, depression, and pain management.

"This acquisition has tremendous implications for our business as we look ahead to our own formulations and branded consumer goods, which will include products such as intranasal medicines and ketamine creams," commented Pouya Farmand, Chief Executive Officer at Levitee Labs. "Bringing a large R&D compounding pharmacy to our Levitee Pharmacies group is a true value-add as we work towards economies of scale as a fully integrated company."

As part of the acquisition announced by Levitee Labs on October 12 th , 2021, Levitee Labs will hold a 51% ownership stake in the Compounding Pharmacy. Levitee Labs will retain the right to acquire the remaining 49% of the Compounding Pharmacy at a pre-determined valuation (multiple of EBITDA – earnings before interest, taxes, depreciation, and amortization). This LOI is non-binding and remains subject to the drafting of definitive agreements, approval from Levitee Labs' board, and regulatory body approvals.

According to a study conducted by the Toronto Rehabilitation Institute 1 , transdermal ketamine and lidocaine was found to be effective in 73% of patients diagnosed with acute neuropathic pain, from a sample size of 854 patient charts. These findings indicate the effectiveness and potential that ketamine-based compounds have on individuals with ailments that require their use.

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401865/

About Levitee Labs Inc.

Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. The Company's current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com .

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee's business plans and proposed products, and the benefits derived from mushroom-infused products; the expected use of proceeds from the Loan; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee's future growth potential; the closing of Tranche 1, including the Levitee's ability to satisfy the Tranche 1 closing conditions; the closing of any future tranches under the Loan, including Levitee's ability to satisfy the closing conditions for future tranches of the Loan; and Levitee's objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee's limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee's public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.

For further information about Levitee Labs Inc., please contact:

Media Contact:
media@leviteelabs.com

Investor and Corporate Communications:
ir@leviteelabs.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M

Revenue of $14.5 million increased 53% from prior year period

Gross profit income of $3.5 million increased 151% from prior year period

Keep reading... Show less

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

  • iX Biopharma will receive an initial US$9 million upfront payment
  • Eligible for up to US$239 million in development and sales milestone payments
  • Double digit royalties on future product sales of any licensed product

IX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Keep reading... Show less
Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch Investor Series today announced their agenda is updated for the Virtual Investor Luncheon on Tuesday November 30. Individual investors, finance professionals, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

Keep reading... Show less

What Does the FDA Think About Psychedelics?

The development of the psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading authority for drug approvals in the US. This federal body determines whether medical products will ultimately reach the hands of patients.

The FDA reviews the clinical data created by established medical studies evaluating the feasibility of drug compounds or products as treatments for specific ailments.

Keep reading... Show less

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China Taiwan Macau and Hong Kong ) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™.

Keep reading... Show less

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.0 million in gross proceeds.

Keep reading... Show less

Top News

Related News